S-(2-carboxy-1-(1H-imidazol-4-yl)ethyl)glutathione: an L-histidine metabolite and precursor of S-(2-carboxy-1-(1H-imidazol-4-yl)ethyl)cysteine found in urine ; most likely formed by the enzymatic degradation of above NM; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3036068 |
| MeSH ID | M0217560 |
| Synonym |
|---|
| s-(2-carboxy-1-(1h-imidazol-4-yl)ethyl)glutathione |
| glycine, n-(s-(2-carboxy-1-(1h-imidazol-4-yl)ethyl)-n-l-gamma-glutamyl-l-cysteinyl)- |
| 134381-44-5 |
| 2-cieglu |
| DTXSID60928594 |
| s-[2-carboxy-1-(1h-imidazol-5-yl)ethyl]cysteinyl-n-gamma-glutamylglycine |
| (2s)-2-amino-5-[[(2r)-2-amino-3-[2-carboxy-1-(1h-imidazol-5-yl)ethyl]sulfanylpropanoyl]-(carboxymethyl)amino]-5-oxopentanoic acid |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||